Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 388

Results For "SSI"

5610 News Found

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr
News | August 12, 2022

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr

Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.


Agriculture Minister Narendra Singh Tomar launches indigenous vaccine for Lumpy Skin disease
Policy | August 11, 2022

Agriculture Minister Narendra Singh Tomar launches indigenous vaccine for Lumpy Skin disease

The vaccine has been developed by the National Equine Research Center, Hisar (Haryana) in collaboration with the Indian Veterinary Research Institute, Izzatnagar (Bareilly)


Vijaya Diagnostic Centre Q1 FY23 revenue down 14.9%
News | August 10, 2022

Vijaya Diagnostic Centre Q1 FY23 revenue down 14.9%

EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%


Sri Lankan President welcomes opening of free hospital by Sri Sathya Sai Baba Trust
Healthcare | August 10, 2022

Sri Lankan President welcomes opening of free hospital by Sri Sathya Sai Baba Trust

The Sri Sathya Sai Sanjeevani Super Speciality Hospital in Batticaloa will begin its operations by conducting free paediatric cardiac care surgeries and interventions in the next few days


ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer
Drug Approval | August 09, 2022

ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy


Briefs: Zydus Lifesciences and Kimia Biosciences
News | August 09, 2022

Briefs: Zydus Lifesciences and Kimia Biosciences

The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.


Health-tech startup Clinikk opens 18 primary care centers across Bengaluru and Hyderabad
Startup | August 09, 2022

Health-tech startup Clinikk opens 18 primary care centers across Bengaluru and Hyderabad

Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.


HERTHENA-Lung02 Phase 3 trial of Patritumab Deruxtecan initiated in patients with EGFR-mutated metastatic non-small cell lung cancer
Clinical Trials | August 09, 2022

HERTHENA-Lung02 Phase 3 trial of Patritumab Deruxtecan initiated in patients with EGFR-mutated metastatic non-small cell lung cancer

Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.


L&T donates a bus to Sankara Eye Hospital for their outreach programme
Healthcare | August 08, 2022

L&T donates a bus to Sankara Eye Hospital for their outreach programme

The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.


Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
News | August 08, 2022

Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%

Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore